The Prospect and Challenges of Therapeutic Vaccines for Parkinson’s Disease
DOI:
https://doi.org/10.54097/1xm7mv49Keywords:
Parkinson’s disease; alpha-synuclein; UB-312.Abstract
Parkinson’s Disease, the second most common neurodegenerative disease worldwide, still poses many problems in treatment, such as the side effects of medications and the lack of therapies for Parkinson’s Disease’s non-motor symptoms. This review discusses a novel measure of coping with the disease—the use of therapeutic vaccines to direct toward alpha-synuclein, a pathological hallmark of Parkinson’s Disease. This review will primarily discuss UB-312, which had undergone a carefully conducted clinical trial, as an example of the therapeutic vaccines. The clinical trial demonstrated that UB-312 could elicit robust immune responses while being safe and well tolerated, suggesting a great potential for therapeutic vaccines in Parkinson’s Disease treatment.
Downloads
References
Beitz J M. Parkinson’s disease: a review. Frontiers in Bioscience-Scholar, 2014, S6(1): 65–74.
Parkinson’s Foundation. Parkinson’s Foundation. /2024-03-22. https://www.parkinson.org/.
Reich S G, Savitt J M. Parkinson’s Disease. Medical Clinics of North America, 2019, 103(2): 337–350.
Matarazzo M, Perez-Soriano A, Stoessl A J. Dyskinesias and levodopa therapy: why wait?. J Neural Transm, 2018, 125(8): 1119–1130.
Sharma V D, Patel M, Miocinovic S. Surgical Treatment of Parkinson’s Disease: Devices and Lesion Approaches. Neurotherapeutics, 2020, 17(4): 1525–1538.
Mak M K, Wong-Yu I S, Shen X, et al. Long-term effects of exercise and physical therapy in people with Parkinson disease. Nat Rev Neurol, 2017, 13(11): 689–703.
Liu T, Lao L. Tai Chi for Patients with Parkinson’s Disease. 2012-05-01/2024-03-11. https://www.nejm.org/doi/full/10.1056/NEJMc1202921.
Parkinson’s Disease: Challenges, Progress, And Promise. National Institute Of Neurological Disorders And Stroke. /2024-03-11.
Dehay B, Bourdenx M, Gorry P, et al. Targeting α-synuclein for treatment of Parkinson’s disease: mechanistic and therapeutic considerations. The Lancet Neurology, 2015, 14(8): 855–866.
Polymeropoulos M H, Lavedan C, Leroy E, et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson’s Disease. Science, 1997, 276(5321): 2045–2047.
Yu H J, Thijssen E, van Brummelen E, et al. A Randomized First‐in‐Human Study With UB‐312, a UBITh® α‐Synuclein Peptide Vaccine. Movement Disorders, 2022, 37(7): 1416–1424.
Nimmo J T, Verma A, Dodart J-C, et al. Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy. Alz Res Therapy, 2020, 12(1).
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
